You are here

VRTX

$129.23

-3.13%

Investor Relations

News & Events

Filter Releases
 
Press Releases
Date Title and Summary View
Mar 28, 2017
-Study in people who have two copies of the F508del mutation demonstrated a mean absolute improvement in ppFEV1 of 4.0 percentage points compared to placebo (p...
Mar 6, 2017
-Vertex to develop CTP-656 for potential use in future combination regimens aimed at treating the underlying cause of CF- -Concert to receive $160 million in cash with potential for $90 million in future regulatory approval milestone payments- BOSTON--(BUSINESS WIRE)-- ...
Dec 19, 2016
LONDON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced it has reached a pricing and reimbursement agreement for ORKAMBI® (lumacaftor/ivacaftor) with the German Federal Association of the Statutory Health Insurances (GKV-SV). ORKAMBI is the first medicine to ...
Nov 7, 2016
- Study met primary endpoint with a statistically significant improvement in absolute change in lung clearance index (LCI2.5) compared to placebo through 24 weeks of treatment - - ORKAMBI was well tolerated with safety data that were similar to data from previous Phase 3 open-label safety study - ...
Oct 27, 2016
- 12 abstracts presented at 30th Annual North American Cystic Fibrosis Conference highlight data from Vertex's CF program - ORLANDO, Fla.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the presentation of long-term data demonstrating t...
Oct 25, 2016
-VX-440 to be evaluated as part of 4-week triple combination dosing with tezacaftor (VX-661) and ivacaftor; VX-152 to be evaluated as part of 2-week triple combination dosing- -Studies to enroll people with cystic fibrosis who have one copy of the F508del mutation and a minimal function mutation a...
Sep 28, 2016
-Approximately 2,400 children ages 6 through 11 have two copies of the F508del mutation in the U.S.- - Vertex revises ORKAMBI revenue guidance for 2016 - BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U....
Aug 15, 2016
-Results from Part A of Phase 3 study in people with a mutation that results in minimal cystic fibrosis transmembrane conductance regulator (CFTR) protein function do not support continuation of the study- -Enrollment complete in Phase 3 study in people with two copies of the F508del mutation- ...
Jul 6, 2016
-Collaboration to explore use of mRNA Therapeutics to treat the underlying cause of CF by enabling cells to produce functional CFTR proteins in the lungs- -Moderna to receive $40 million upfront, made up of a $20 million cash payment and a $20 million convertible note investment, with pot...
Jun 10, 2016
-Real-world data presented at ECFS show long-term impact of KALYDECO across multiple measures of disease- -Data from Phase 3 safety study of ORKAMBI in children ages 6-11 presented today at ECFS- BASEL, Switzerland--(BUSINESS WIRE)-- Vertex Pharmaceuticals I...
May 31, 2016
-Approximately 2,400 children ages 6 to 11 have two copies of the F508del mutation in the U.S.- -Target review date of September 30, 2016 set for the FDA's decision on the application- BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRT...
Mar 8, 2016
-In Australia, approximately 1,000 people with CF ages 12 and older have two copies of the F508del mutation- -ORKAMBI reimbursement process already underway in Australia- LONDON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced tha...
Feb 24, 2016
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced it has awarded the company's 2016 Cystic Fibrosis (CF) Circle of Care grants, totaling approximately $1 million, to 18 non-profit medical, academic, patient and community organizations. In its second yea...
Feb 5, 2016
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) for the use of KALYDECO® (ivacaftor) in people with cystic ...
Jan 26, 2016
-Approximately 1,500 people in Canada are ages 12 and older and have two copies of the F508del mutation, the most common genetic form of the disease- BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has approved...
Page:
...
Next Last